Study of Stem Cell Function Using Microarray Experiments
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Old Data and Friends Improve with Age: Advancements with the Updated Tools of Genenetwork
bioRxiv preprint doi: https://doi.org/10.1101/2021.05.24.445383; this version posted May 25, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Old data and friends improve with age: Advancements with the updated tools of GeneNetwork Alisha Chunduri1, David G. Ashbrook2 1Department of Biotechnology, Chaitanya Bharathi Institute of Technology, Hyderabad 500075, India 2Department of Genetics, Genomics and Informatics, University of Tennessee Health Science Center, Memphis, TN 38163, USA Abstract Understanding gene-by-environment interactions is important across biology, particularly behaviour. Families of isogenic strains are excellently placed, as the same genome can be tested in multiple environments. The BXD’s recent expansion to 140 strains makes them the largest family of murine isogenic genomes, and therefore give great power to detect QTL. Indefinite reproducible genometypes can be leveraged; old data can be reanalysed with emerging tools to produce novel biological insights. To highlight the importance of reanalyses, we obtained drug- and behavioural-phenotypes from Philip et al. 2010, and reanalysed their data with new genotypes from sequencing, and new models (GEMMA and R/qtl2). We discover QTL on chromosomes 3, 5, 9, 11, and 14, not found in the original study. We narrowed down the candidate genes based on their ability to alter gene expression and/or protein function, using cis-eQTL analysis, and variants predicted to be deleterious. Co-expression analysis (‘gene friends’) and human PheWAS were used to further narrow candidates. -
Nuclear ELAC2 Overexpression Is Associated with Increased Hazard for Relapse After Radical Prostatectomy
www.oncotarget.com Oncotarget, 2019, Vol. 10, (No. 48), pp: 4973-4986 Research Paper Nuclear ELAC2 overexpression is associated with increased hazard for relapse after radical prostatectomy Cornelia Schroeder1,2,*, Elham Navid-Hill1,*, Jan Meiners2, Claudia Hube-Magg1, Martina Kluth1, Georgia Makrypidi-Fraune1, Ronald Simon1, Franziska Büscheck1, Andreas M. Luebke1, Cosima Goebel1, Dagmar S. Lang1, Sören Weidemann1, Emily Neubauer1, Andrea Hinsch1, Frank Jacobsen1, Patrick Lebok1, Uwe Michl3, Dirk Pehrke3,4, Hartwig Huland3, Markus Graefen3, Thorsten Schlomm3,4, Guido Sauter1 and Doris Höflmayer1 1Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany 2General, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany 3Martini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany 4Department of Urology, Charité - Universitätsmedizin Berlin, Berlin, Germany *These authors contributed equally to this work Correspondence to: Ronald Simon, email: [email protected] Keywords: ELAC2; HPC2; prostate cancer; prognosis; tissue microarray Received: November 17, 2018 Accepted: July 21, 2019 Published: August 13, 2019 Copyright: Schroeder et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT ELAC2 is a ubiquitously expressed enzyme potentially involved in tRNA processing and cell signaling pathways. Mutations of the ELAC2 gene have been found to confer increased prostate cancer susceptibility in families. ELAC2 protein expression was analyzed by immunohistochemistry in 9,262 patients and Kaplan-Meier curves of PSA recurrence-free survival were calculated in 8,513 patients treated with radical prostatectomy. -
A Yeast Phenomic Model for the Influence of Warburg Metabolism on Genetic Buffering of Doxorubicin Sean M
Santos and Hartman Cancer & Metabolism (2019) 7:9 https://doi.org/10.1186/s40170-019-0201-3 RESEARCH Open Access A yeast phenomic model for the influence of Warburg metabolism on genetic buffering of doxorubicin Sean M. Santos and John L. Hartman IV* Abstract Background: The influence of the Warburg phenomenon on chemotherapy response is unknown. Saccharomyces cerevisiae mimics the Warburg effect, repressing respiration in the presence of adequate glucose. Yeast phenomic experiments were conducted to assess potential influences of Warburg metabolism on gene-drug interaction underlying the cellular response to doxorubicin. Homologous genes from yeast phenomic and cancer pharmacogenomics data were analyzed to infer evolutionary conservation of gene-drug interaction and predict therapeutic relevance. Methods: Cell proliferation phenotypes (CPPs) of the yeast gene knockout/knockdown library were measured by quantitative high-throughput cell array phenotyping (Q-HTCP), treating with escalating doxorubicin concentrations under conditions of respiratory or glycolytic metabolism. Doxorubicin-gene interaction was quantified by departure of CPPs observed for the doxorubicin-treated mutant strain from that expected based on an interaction model. Recursive expectation-maximization clustering (REMc) and Gene Ontology (GO)-based analyses of interactions identified functional biological modules that differentially buffer or promote doxorubicin cytotoxicity with respect to Warburg metabolism. Yeast phenomic and cancer pharmacogenomics data were integrated to predict differential gene expression causally influencing doxorubicin anti-tumor efficacy. Results: Yeast compromised for genes functioning in chromatin organization, and several other cellular processes are more resistant to doxorubicin under glycolytic conditions. Thus, the Warburg transition appears to alleviate requirements for cellular functions that buffer doxorubicin cytotoxicity in a respiratory context. -
Intimate Relations—Mitochondria and Ageing
International Journal of Molecular Sciences Review Intimate Relations—Mitochondria and Ageing Michael Webb and Dionisia P. Sideris * Mitobridge Inc., an Astellas Company, 1030 Massachusetts Ave, Cambridge, MA 02138, USA; [email protected] * Correspondence: [email protected] Received: 29 August 2020; Accepted: 6 October 2020; Published: 14 October 2020 Abstract: Mitochondrial dysfunction is associated with ageing, but the detailed causal relationship between the two is still unclear. Wereview the major phenomenological manifestations of mitochondrial age-related dysfunction including biochemical, regulatory and energetic features. We conclude that the complexity of these processes and their inter-relationships are still not fully understood and at this point it seems unlikely that a single linear cause and effect relationship between any specific aspect of mitochondrial biology and ageing can be established in either direction. Keywords: mitochondria; ageing; energetics; ROS; gene regulation 1. Introduction The last two decades have witnessed a dramatic transformation in our view of mitochondria, their basic biology and functions. While still regarded as functioning primarily as the eukaryotic cell’s generator of energy in the form of adenosine triphosphate (ATP) and nicotinamide adenine dinucleotide (reduced form; NADH), mitochondria are now recognized as having a plethora of functions, including control of apoptosis, regulation of calcium, forming a signaling hub and the synthesis of various bioactive molecules. Their biochemical functions beyond ATP supply include biosynthesis of lipids and amino acids, formation of iron sulphur complexes and some stages of haem biosynthesis and the urea cycle. They exist as a dynamic network of organelles that under normal circumstances undergo a constant series of fission and fusion events in which structural, functional and encoding (mtDNA) elements are subject to redistribution throughout the network. -
Atlas Journal
Atlas of Genetics and Cytogenetics in Oncology and Haematology Home Genes Leukemias Solid Tumours Cancer-Prone Deep Insight Portal Teaching X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA Atlas Journal Atlas Journal versus Atlas Database: the accumulation of the issues of the Journal constitutes the body of the Database/Text-Book. TABLE OF CONTENTS Volume 12, Number 6, Nov-Dec 2008 Previous Issue / Next Issue Genes BCL8 (B-cell CLL/lymphoma 8) (15q11). Silvia Rasi, Gianluca Gaidano. Atlas Genet Cytogenet Oncol Haematol 2008; 12 (6): 781-784. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/BCL8ID781ch15q11.html CDC25A (Cell division cycle 25A) (3p21). Dipankar Ray, Hiroaki Kiyokawa. Atlas Genet Cytogenet Oncol Haematol 2008; 12 (6): 785-791. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/CDC25AID40004ch3p21.html CDC73 (cell division cycle 73, Paf1/RNA polymerase II complex component, homolog (S. cerevisiae)) (1q31.2). Leslie Farber, Bin Tean Teh. Atlas Genet Cytogenet Oncol Haematol 2008; 12 (6): 792-797. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/CDC73D181ch1q31.html EIF3C (eukaryotic translation initiation factor 3, subunit C) (16p11.2). Daniel R Scoles. Atlas Genet Cytogenet Oncol Haematol 2008; 12 (6): 798-802. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/EIF3CID44187ch16p11.html ELAC2 (elaC homolog 2 (E. coli)) (17p11.2). Yang Chen, Sean Tavtigian, Donna Shattuck. Atlas Genet Cytogenet Oncol Haematol 2008; 12 (6): 803-806. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/ELAC2ID40437ch17p11.html FOXM1 (forkhead box M1) (12p13). Jamila Laoukili, Monica Alvarez Fernandez, René H Medema. -
The MRPP1/MRPP2 Complex Is a Trna-Maturation Platform in Human Mitochondria Linda Reinhard1,2,†, Sagar Sridhara1,2,† and B
Published online 13 October 2017 Nucleic Acids Research, 2017, Vol. 45, No. 21 12469–12480 doi: 10.1093/nar/gkx902 The MRPP1/MRPP2 complex is a tRNA-maturation platform in human mitochondria Linda Reinhard1,2,†, Sagar Sridhara1,2,† and B. Martin Hallberg¨ 1,2,3,* 1Department of Cell and Molecular Biology, Karolinska Institutet, 17177 Stockholm, Sweden, 2Rontgen-¨ Angstr˚ om-Cluster,¨ Karolinska Institutet Outstation, Centre for Structural Systems Biology (CSSB), DESY-Campus, 22607 Hamburg, Germany and 3European Molecular Biology Laboratory, Hamburg Unit, 22603 Hamburg, Germany Received August 07, 2017; Revised September 11, 2017; Editorial Decision September 24, 2017; Accepted September 25, 2017 ABSTRACT discrete, compact structures about 100 nm in diameter (3,4). The genome is transcribed bi-directionally to produce long Mitochondrial polycistronic transcripts are exten- polycistronic heavy- and light-strand precursor RNA tran- sively processed to give rise to functional mR- scripts. These transcripts must be further processed to re- NAs, rRNAs and tRNAs; starting with the release of lease the mature mitochondrial RNAs essential for organel- tRNA elements through 5 -processing by RNase P lar translation, and hence for respiratory chain biogenesis (MRPP1/2/3-complex) and 3-processing by RNase (5–7). The large majority of mRNA and rRNA elements are Z (ELAC2). Here, we show using in vitro experi- flanked by one or more tRNA elements. In what is known ments that MRPP1/2 is not only a component of as the tRNA punctuation model (6), excision of the tRNA the mitochondrial RNase P but that it retains the elements releases all other elements and is a prerequisite for tRNA product from the 5-processing step and signif- RNA maturation. -
Whole Exome HBV DNA Integration Is Independent of the Intrahepatic HBV Reservoir in Hbeag-Negative Chronic Hepatitis B
Hepatology Original research Gut: first published as 10.1136/gutjnl-2020-323300 on 21 December 2020. Downloaded from Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg- negative chronic hepatitis B Valentina Svicher,1 Romina Salpini,1 Lorenzo Piermatteo,1 Luca Carioti,1 Arianna Battisti,1,2 Luna Colagrossi,1,3 Rossana Scutari,1 Matteo Surdo,4 Valeria Cacciafesta,4 Andrea Nuccitelli,4 Navjyot Hansi,2 Francesca Ceccherini Silberstein,1 Carlo Federico Perno,5 Upkar S Gill,2 Patrick T F Kennedy 2 ► Additional material is ABSTRACT published online only. To view, Objective The involvement of HBV DNA integration in Significance of this study please visit the journal online promoting hepatocarcinogenesis and the extent to which (http:// dx. doi. org/ 10. 1136/ What is already known on this subject? gutjnl- 2020- 323300). the intrahepatic HBV reservoir modulates liver disease progression remains poorly understood. We examined ► Hepatitis B ‘e’ antigen (HBeAg)- negative phase For numbered affiliations see of HBV infection is associated with a wide end of article. the intrahepatic HBV reservoir, the occurrence of HBV DNA integration and its impact on the hepatocyte disease spectrum, ranging from quiescent low viraemic disease to chronic HBeAg- negative Correspondence to transcriptome in hepatitis B ’e’ antigen (HBeAg)-negative Dr Patrick T F Kennedy, Barts chronic hepatitis B (CHB). hepatitis, with a high risk of evolution to Liver Centre, Immunobiology, Design Liver tissue from 84 HBeAg-negative patients cirrhosis and hepatocellular carcinoma. Blizard Institute, Barts and The with CHB with low (n=12), moderate (n=25) and high ► Hepatitis B surface antigen (HBsAg) and London School of Medicine (n=47) serum HBV DNA was analysed. -
(12) United States Patent (10) Patent No.: US 7,851,162 B2 Lubifiski Et Al
US007851-162B2 (12) United States Patent (10) Patent No.: US 7,851,162 B2 Lubifiski et al. (45) Date of Patent: Dec. 14, 2010 (54) DETERMINING A PREDISPOSITION TO The Gene Card for NOD2 found onlineathttp://www.genecards.org/ CANCER cgi-bin/carddisp.pl?gene=NOD2&search=nod2 and accessed Feb. 12, 2010.* (76) Inventors: Jan Lubinski, Ul. Akacjowa 2, Szczecin The Gene Card for CDKN2A found online at http://www.genecards. (PL) 71-253; Janina Suchy, ul. org/cgi-bin/carddisp.pl?gene=CDKN2A&search=cdkn2a and Ledochoskiego 7/10, Szczecin (PL) accessed Feb. 12, 2010.* 7 1-004; Grzegorz Kurzawski, ul. International Search Report issued by the International Searching Authority (ISA/EP) on Jul. 28, 2005 in connection with PCT Inter Tomaszowska 24/9, Szczecin (PL) national Application No. PCT/PL2005/000006, filed Jan. 15, 2005. 71-671; Tadeusz Debniak, ul. Rteciowa International Preliminary Reporton Patentability issued Jul. 17, 2006 13, Szczecin (PL) 70-736: Cezary in connection with PCT International Application No. PCT/PL2005/ Cybulski, 72-005 Przeclaw 58c/8, 000006, filed Jan. 15, 2005. Przeclaw (PL) 72-005 Written opinion of the International Searching Authority issued on Jul. 15, 2006 in connection with PCT International Application No. (*) Notice: Subject to any disclaimer, the term of this PCT/PL2005/OOOOO6. patent is extended or adjusted under 35 Examination Report issued Nov. 5, 2009 in connection with Euro U.S.C. 154(b) by 114 days. pean Patent Application No. 05704666.6. May 14, 2010 Reply to the Examination Report issued Nov. 5, 2009 (21) Appl. No.: 12/220,761 in connection with European Patent Application No. -
Title: a Yeast Phenomic Model for the Influence of Warburg Metabolism on Genetic
bioRxiv preprint doi: https://doi.org/10.1101/517490; this version posted January 15, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. 1 Title Page: 2 3 Title: A yeast phenomic model for the influence of Warburg metabolism on genetic 4 buffering of doxorubicin 5 6 Authors: Sean M. Santos1 and John L. Hartman IV1 7 1. University of Alabama at Birmingham, Department of Genetics, Birmingham, AL 8 Email: [email protected], [email protected] 9 Corresponding author: [email protected] 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 1 bioRxiv preprint doi: https://doi.org/10.1101/517490; this version posted January 15, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. 26 Abstract: 27 Background: 28 Saccharomyces cerevisiae represses respiration in the presence of adequate glucose, 29 mimicking the Warburg effect, termed aerobic glycolysis. We conducted yeast phenomic 30 experiments to characterize differential doxorubicin-gene interaction, in the context of 31 respiration vs. glycolysis. The resulting systems level biology about doxorubicin 32 cytotoxicity, including the influence of the Warburg effect, was integrated with cancer 33 pharmacogenomics data to identify potentially causal correlations between differential 34 gene expression and anti-cancer efficacy. -
Loss of Heterozygosity of the Putative Prostate Cancer Susceptibility Gene HPC2/ ELAC2 Is Uncommon in Sporadic and Familial Prostate Cancer1
[CANCER RESEARCH 61, 8651–8653, December 15, 2001] Advances in Brief Loss of Heterozygosity of the Putative Prostate Cancer Susceptibility Gene HPC2/ ELAC2 Is Uncommon in Sporadic and Familial Prostate Cancer1 Yu-Qun Wu, Hong Chen, Mark A. Rubin, Kirk J. Wojno, and Kathleen A. Cooney2 Departments of Internal Medicine [Y-Q. W., H. C., K. A. C.], Urology [M. A. R., K. A. C.], and Pathology [M. A. R.], University of Michigan Medical School, Ann Arbor, Michigan 48109-0946, and St. John Hospital and Medical Center, Detroit, Michigan 48236 [K. J. W.] Abstract setting of LOH, the remaining allele is presumed to be nonfunctional, either because of a preexisting inherited mutation or because of a sec- The recognition that prostate cancer clusters within families has led to the ondary sporadic mutation. If the newly identified hereditary prostate search for prostate cancer susceptibility genes. Recently, the HPC2/ELAC2 cancer gene HPC2/ELAC2 functions as a tumor suppressor gene in gene on chromosome 17p has been identified as a potential prostate cancer predisposition gene using both family based as well as case-control studies. prostate cancer, we hypothesized that deletion of 17p may be observed in Many cancer susceptibility genes act as tumor suppressor genes in which some familial prostate cancer cases. Furthermore, tumor suppressor genes inactivation of one allele in the tumor can be detected via loss of heterozy- important in the pathogenesis of hereditary cancers are sometimes ob- gosity (LOH). To determine whether the HPC2/ELAC2 gene demonstrates served to be deleted in sporadic cancers (16). Therefore, we set out to significant LOH in sporadic and familial prostate cancers, paired tumor and determine whether allelic loss of HPC2/ELAC2 could be detected in a set normal DNA samples were isolated using microdissection techniques from 44 of both familial and sporadic prostate cancer cases. -
The First Korean Case of Combined Oxidative Phos Phorylation
Case report KimKorean YA, Jet Pediatr al. • First 2017;60(12):408-412 Korean case of COXPD-17 https://doi.org/10.3345/kjp.2017.60.12.408 pISSN 1738-1061•eISSN 2092-7258 Korean J Pediatr The First Korean case of combined oxidative phos phorylation deficiency-17 diagnosed by clinical and molecular investigation Young A Kim, MD1, Yoo-Mi Kim, MD, PhD1, Yun-Jin Lee, MD, PhD1, Chong Kun Cheon, MD, PhD1,2 1Department of Pediatrics, Pusan National University Children’s Hospital, Yangsan, 2Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea Combined oxidative phosphorylation deficiency-17 (COXPD-17) is very rare and is caused by homozygous Corresponding author: Chong Kun Cheon, MD, or compound heterozygous mutations in the ELAC2 gene on chromosome 17p12. The ELAC2 gene PhD Department of Pediatrics, Pusan National University functions as a mitochondrial tRNA processing gene, and only 4 different pathogenic mutations have been Children's Hospital, 20 Geumo-ro, Mulgeum-eup, reported in ELAC2-associated mitochondrial dysfunction involving oxidative phosphorylation. Affected Yangsan 50612, Korea patients show various clinical symptoms and prognosis, depending on the genotype. We report a novel Tel: +82-55-360-3158 mutation in the ELAC2 gene (c.95C>G [p.Pro32Arg], het), in an infant with COXPD-17 who presented Fax: +82-55-360-2181 E-mail: [email protected] with encephalopathy including central apnea and intractable epilepsy, and growth and developmental retardation. During hospitalization, consistently elevated serum lactic acid levels were noted, indicative Received: 7 August, 2017 of mitochondrial dysfunction. The patient suddenly died of shock of unknown cause at 5 months of age. -
POLYMORPHISMS of HPC2/ELAC2 and SRD5A2 (5Α-Reductase Type II) GENES in PROSTATE CANCER İzmirli M1,*, Arikan B2, Bayazit Y3, Alptekin D4
BJMG 14/1 (2011) 31-36 10.2478/v10034-011-0015-2 ORIGINAL ARTICLE POLYMORPHISMS OF HPC2/ELAC2 AND SRD5A2 (5α-Reductase Type II) GENES IN PROSTATE CANCER İzmirli M1,*, Arikan B2, Bayazit Y3, Alptekin D4 *Corresponding Author: Muzeyyen İzmirli, Department of Medical Biology, Faculty of Medicine, Bezmialem Vakif University, 34093, Istanbul, Turkey; Tel.: +90-212-523-37-19, Fax: +90-212-523-23-26; E-mail: [email protected]. ABSTRACT INTRODUCTION Prostate cancer is the proliferation of malignant Prostate cancer results from alteration of the bal- cells in the prostate gland. The HPC2/ELAC2 gene on ance between cell proliferation and cell death in the chromosome 17p11.2 and SRD5A2 gene on chromo- prostate gland. This cancer accounts for 32% of total some 2p22-23 are predisposing genetic factors. We cancers in men [1]. Prostate cancer is caused by hor- examined the relationship between Ser217Leu and monal, dietary, environmental and genetic factors. The Ala541Thr polymorphisms of the former gene, and genes HPC2/ ELAC2, SRD5A2 (5α-reductase type II), Ala49Thr and Val89Leu polymorphisms of the latter HPC1 (hereditary prostate cancer 1), AR (androgen re- gene to prostate cancer in Turkish men, using the poly- ceptor), PSA (prostate specific antigen) are among the merase chain reaction (PCR) method and appropriate genes responsible for it [1]. restriction enzymes. The HPC2/ ELAC2 gene Ser217- The HPC2/ELAC2 gene belongs to a family of pros- Leu and SRD5A2 gene Ala49Thr polymorphisms were tate cancer susceptibility genes which encode an evolu- associated with an increased risk of prostate cancer in tionarily conserved metal-dependent hydrolase [1] that is Turkish men [for the HPC2/ELAC2 gene Ser217Leu 3’ processing endoribonuclease and to interact a compo- polymorphism: odds ratio (OR) 2.7; confidence inter- nent of the mitotic apparatus is a γ tubulin.